A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer
Trial ID or NCT#
Status
Purpose
This was a Phase 2a trial to investigate the safety and biological activity of the RIX-2 Regimen in patients with untreated, resectable squamous cell cancer of the head and neck (HNSCC).
Official Title
A Phase 2, Open-label Trial of the Safety and Biological Effect of Subcutaneous IRX-2 (With Cyclophosphamide, Indomethacin, and Zinc) in Patients With Resectable Cancer of the Head and Neck
Eligibility Criteria
- * Pathologically confirmed (histology) Squamous Cell Carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx.* No prior surgery, radiation therapy or chemotherapy of this tumor other than biopsy or emergency procedure required for supportive care.* Clinically staged Stage II, III, or IVA cancer, assessed to be surgically resectable with curative intent.* Life Expectancy of greater than 6 months
- * Stage IVB Squamous Cell Carcinoma* Use of any investigational agent within the previous 30 days* Uncontrolled cardiovascular disease* Myocardial infarction within the last 3 months* Abnormal hemoglobin, neutrophil, lymphocyte or platelet counts* Positive for hepatitis B or C or HIV* Evidence of distant metastases* Clinical gastritis or peptic ulcer within the last 6 months* Stroke within the last six months
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Cancer Clinical Trials Office
650-498-7061
View on ClinicalTrials.gov